Therapeutic strategies targeting B-cells in multiple sclerosis

Autoimmunity Reviews

Volumn 15, Issue 7, 2016, Pages 714-718

  Milo, Ron ^a,b  

^a Institute of Hematology   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

B cells; CD20; Multiple sclerosis; Ocrelizumab

Indexed keywords

ALEMTUZUMAB; ATACICEPT; CD20 ANTIGEN; CD52 ANTIGEN; CYTOKINE; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; MONOCLONAL ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; MONOCYTE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; HUMANS; MULTIPLE SCLEROSIS;

EID: 84963542806     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.03.006     Document Type: Review

References (32)

1. Barun B., Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 2012, 142:31-37.
2. Dalakas M.C. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008, 70:2252-2260.
3. Alexopoulos H., Biba A., Dalakas M.C. Anti-B-cell therapies in autoimmune neurological diseases: rationale and efficacy trials. Neurotherapeutics 2016, 13:20-33.
4. Gasperi C., Stüve O., Hemmer B. B cell-directed therapies in multiple sclerosis. Neurodegener Dis Manag 2016, 6:37-47.
5. Lassmann H., Brück W., Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001, 7:115-121.
6. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004, 14:164-174.
7. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130(Pt 4):1089-1104.
8. Hemmer B., Nessler S., Zhou D., Kieseier B., Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006, 2:201-211.
9. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125:1678-1685.
10. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., HERMES Trial Group, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
11. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., et al. OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-471.
12. Hauser S.L., Comi G.C., Hartung H.-P., Selmaj K., Traboulsee A., Bar-Or A., et al. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, phase III OPERA I and II studies. Mult Scler 2015, 21(Suppl.):61-62. on behalf of the OPERA I and II clinical investigators, [Abstract 190].
13. Montalban X., Hemmer B., Rammohan K., Giovannoni G., de Seze J., Bar-Or A., et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, phase III ORATORIO study. Mult Scler 2015, 21(Suppl.):781-782. on behalf of the ORATORIO clinical investigators, [Abstract 228].
14. Emery P., Rigby W., Tak P.P., Dörner T., Olech E., Martin C., et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One 2014, 9.
15. Wolinsky J., Arnold D., Bar-Or A., de Seze J., Giovannoni G., Hemmer B., et al. Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a phase III, placebo-controlled trial. American Committee on Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, New Orleans, Louisiana February 18-20, 2016, [Abstract LB1.3 LB148].
16. Sorensen P.S., Lisby S., Grove R., Derosier F., Shackelford S., Havrdova E., et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014, 82:573-581.
17. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
18. Clinicaltrials.gov. [accessed 13 February 2016]. https://clinicaltrials.gov/ct2/show/NCT00882999.
19. Kantonsspital St Gallen. [Accessed 13 February 2016]. https://research.kssg.ch/Projekte/35126.
20. Houssiau F.A., Doria A. Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?. Ann Rheum Dis 2016, 75:321-322.
21. Kappos L., Hartung H.P., Freedman M.S., Boyko A., Radü E.W., Mikol D.D., et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double blind, phase 2 trial. Lancet Neurol 2014, 13:353-363.
22. Clinicaltrials.gov. [Accessed 13 February 2016]. https://clinicaltrials.gov/ct2/show/NCT00624468.
23. Luhder F., Graold R. Trial and error in clinical studies: lessons from ATAMS. Lancet Neurol 2014, 13:340-341.
24. Hartung H.P., Kieseier B.C. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010, 3:205-216.
25. Rao S., Sancho J., Campos-Rivera J., Boutin P., Severy P., Weeden T., et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012, 7.
26. Wiendl H., Kieseier B. Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. Nat Rev Neurol 2013, 9:125-126.
27. Cohen J.A., Coles A.J., Arnold D.L., Confavreux C., Fox E.J., Hartung H.P., et al. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380:1819-1828.
28. Coles A.J., Twyman C.L., Arnold D.L., Cohen J.A., Confavreux C., Fox E.J., CARE-MS II Investigators, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
29. Havrdova E., Arnold D.L., Cohen J.A., Compston D.A.S., Fox E.J., Hartung H.-P., et al. Durable efficacy of alemtuzumab on clinical outcomes over 5 years in treatment-naïve patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE-MS I extension study. Mult Scler 2015, 21(Suppl.):45. [Abstract 152].
30. Jones J.L., Phuah C.L., Cox A.L., Thompson S.A., Ban M., Shawcross J., et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (campath-1H). J Clin Invest 2009, 119:2052-2061.
31. Kala M., Miravalle A., Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol 2011, 235:9-17.
32. Loleit V., Biberacher V., Hemmer B. Current and future therapies targeting the immune system in multiple sclerosis. Curr Pharm Biotechnol 2014, 15:276-296.